Laxiriva

Sodium hydrogen carbonate, potassium chloride, sodium chloride, and macrogol 3350, the active ingredients in Laxiriva, are laxatives presented as an oral formulation for oral use. It helps relieve occasional constipation and can be used for bowel cleansing in adults. GNH USA supplies Laxiriva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Laxiriva is an oral osmotic laxative used to manage conditions affecting bowel motility and stool consistency. - Constipation: softens stool and promotes regular bowel movements. - Bowel preparation: facilitates colon cleansing before diagnostic procedures such as colonoscopy. - Irritable bowel syndrome with constipation: improves stool frequency and reduces discomfort.

Laxiriva may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Abdominal bloating: feeling of fullness or swelling in the abdomen. - Flatulence: increased intestinal gas. - Nausea: mild sensation of wanting to vomit. - Mild abdominal cramping: intermittent stomach discomfort. - Diarrhoea: loose or watery stools. - Electrolyte imbalance: mild changes in sodium or potassium levels.

Serious or Rare Side Effects: - Severe dehydration: excessive fluid loss requiring medical attention. - Severe abdominal pain: intense, persistent pain. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Significant electrolyte disturbances: may lead to cardiac arrhythmia. - Rectal bleeding: unusual blood in stool.

Before using Laxiriva, consider the following safety measures. - Assess renal function: impaired kidneys may affect electrolyte handling. - Monitor electrolyte balance: especially in patients on diuretics or with cardiac disease. - Use with caution in the elderly: higher risk of dehydration. - Avoid in complete bowel obstruction: may worsen blockage. - Store at ambient temperature: keep in original packaging, protect from moisture.

Laxiriva can interact with other medicines, requiring attention to avoid complications.

Major Interactions (Avoid): - Concurrent osmotic laxatives: risk of severe electrolyte loss. - Loop diuretics: increased risk of dehydration and electrolyte depletion. - Lithium therapy: altered lithium plasma concentrations. - Anticholinergic agents: reduced laxative efficacy.

Moderate Interactions (Monitor Closely): - NSAIDs: potential impact on renal function when combined. - ACE inhibitors or ARBs: monitor kidney function and electrolytes.